mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
出版年份 2012 全文链接
标题
mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 24, Issue 4, Pages 965-973
出版商
Oxford University Press (OUP)
发表日期
2012-12-08
DOI
10.1093/annonc/mds605
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma
- (2011) L. Tiong et al. BRITISH JOURNAL OF SURGERY
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization
- (2011) Roopinder Gillmore et al. JOURNAL OF HEPATOLOGY
- Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models
- (2011) Ju Hyun Shim et al. RADIOLOGY
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
- (2010) Riad Salem et al. GASTROENTEROLOGY
- Imaging Response in the Primary Index Lesion and Clinical Outcomes Following Transarterial Locoregional Therapy for Hepatocellular Carcinoma
- (2010) Ahsun Riaz JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study
- (2010) Renumathy Dhanasekaran et al. HPB
- Assessment of Tumor Necrosis of Hepatocellular Carcinoma After Chemoembolization: Diffusion-Weighted and Contrast-Enhanced MRI With Histopathologic Correlation of the Explanted Liver
- (2009) Lorenzo Mannelli et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma
- (2009) Alejandro Forner et al. CANCER
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
- (2009) Johannes Lammer et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes
- (2009) Riad Salem et al. GASTROENTEROLOGY
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
- (2009) Sean F. Altekruse et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started